MARKET

DGX

DGX

Quest Diagnostics Inc
NYSE
135.42
-2.13
-1.55%
Pre Market: 135.42 0 0.00% 08:02 04/26 EDT
OPEN
137.55
PREV CLOSE
137.55
HIGH
138.61
LOW
134.13
VOLUME
1
TURNOVER
0
52 WEEK HIGH
148.62
52 WEEK LOW
117.60
MARKET CAP
15.04B
P/E (TTM)
18.22
1D
5D
1M
3M
1Y
5Y
Results: Quest Diagnostics Incorporated Beat Earnings Expectations And Analysts Now Have New Forecasts
Quest Diagnostics Incorporated (NYSE:DGX) just released its latest first-quarter results. Revenues beat analyst predictions by 3.5% to hit US$2.4b. Statutory earnings per share came in at US$1.72, beating expectations by 7.5%. The company is expected to grow slower than the industry in the coming years. Quest Diagnostics analysts have not updated their expectations for the company for next year.
Simply Wall St · 8h ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Apellis Pharmaceuticals (APLS), Quest Diagnostics (DGX) and Healthcare Services (HCSG)
Analysts have new ratings on Apellis Pharmaceuticals (APLS), Quest Diagnostics (DGX – Research Report) and Healthcare Services (HCSG – Research report) The Street suggests a Strong Buy analyst consensus rating for the Healthcare sector.
TipRanks · 13h ago
Quest Diagnostics: A Hold Rating Amid Solid Earnings and Strategic Caution
TipRanks · 14h ago
Quest Diagnostics Is Maintained at Equal-Weight by Barclays
Dow Jones · 1d ago
Quest Diagnostics Price Target Raised to $144.00/Share From $138.00 by Barclays
Dow Jones · 1d ago
Barclays Maintains Equal-Weight on Quest Diagnostics, Raises Price Target to $144
Benzinga · 1d ago
Labcorp beats quarterly estimates on strong testing demand
Labcorp beats quarterly estimates on strong testing demand. Growing demand for specialty tests boosted sales at its diagnostics business. More people in the U.S. Are catching up on medical procedures and routine check-ups. The company reported first-quarter profit of $3.68 per share.
Reuters · 1d ago
QUEST DIAGNOSTICS INC <DGX.N>: BARCLAYS RAISES TARGET PRICE TO $144 FROM $138
Reuters · 1d ago
More
About DGX
Quest Diagnostics Incorporated is a provider of diagnostic information services. The Company operates through the DIS segment, which provides diagnostic information services to a range of customers within its primary customer channels: physicians, hospitals, and patients and consumers. It provides diagnostic information services for infectious diseases, such as tuberculosis (e.g., T.SPOT.TB and Quantiferon offerings) and tick-borne disease (e.g., Accutix offering). Its comprehensive offerings in drug monitoring and toxicology, in neurology diagnostics, in advanced cardiovascular diagnostic information services (e.g. CARDIO IQ and Cleveland HeartLab offerings through its Cardiometabolic Center of Excellence), and in cancer diagnostics. Its Diagnostic Solutions business consists of its risk assessment services and healthcare information technology businesses. Its risk assessment service, ExamOne, is a provider of risk assessment services for the life insurance industry in North America.

Webull offers Quest Diagnostics Inc stock information, including NYSE: DGX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DGX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DGX stock methods without spending real money on the virtual paper trading platform.